相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。DIVERSITY AND BIOLOGY OF CANCER-ASSOCIATED FIBROBLASTS
Giulia Biffi et al.
PHYSIOLOGICAL REVIEWS (2021)
Mechanisms of Therapeutic Antitumor Monoclonal Antibodies
Li-Chung Tsao et al.
CANCER RESEARCH (2021)
Atractylenolide I enhances responsiveness to immune checkpoint blockade therapy by activating tumor antigen presentation
Hanchen Xu et al.
JOURNAL OF CLINICAL INVESTIGATION (2021)
Paradoxical effects of chemotherapy on tumor relapse and metastasis promotion
Crescenzo D'Alterio et al.
SEMINARS IN CANCER BIOLOGY (2020)
Molecular therapies for HCC: Looking outside the box
Sandrine Faivre et al.
JOURNAL OF HEPATOLOGY (2020)
The proteasome 19S cap and its ubiquitin receptors provide a versatile recognition platform for substrates
Kirby Martinez-Fonts et al.
NATURE COMMUNICATIONS (2020)
Identification of P-Rex1 in the Regulation of Liver Cancer Cell Proliferation and Migration via HGF/c-Met/Akt Pathway
Wancheng Qiu et al.
ONCOTARGETS AND THERAPY (2020)
Targeted therapy for hepatocellular carcinoma
Ao Huang et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2020)
Inhibition of PSMD4 blocks the tumorigenesis of hepatocellular carcinoma
Mei-Juan Cai et al.
GENE (2019)
Hepatocellular Carcinoma
Augusto Villanueva
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Rpn10 promotes tumor progression by regulating hypoxia-inducible factor 1 alpha through the PTEN/Akt signaling pathway in hepatocellular carcinoma
Zhiyuan Jiang et al.
CANCER LETTERS (2019)
Ubiquitylation at the crossroads of development and disease
Michael Rape
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2018)
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
Masatoshi Kudo et al.
LANCET (2018)
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
G. K. Abou-Alfa et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Proteasome Structure and Assembly
Lauren Budenholzer et al.
JOURNAL OF MOLECULAR BIOLOGY (2017)
Kinase inhibitors and monoclonal antibodies in oncology: clinical implications
Helen Gharwan et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
The ubiquitin-proteasome system and its potential application in hepatocellular carcinoma therapy
Yan-Jie Chen et al.
CANCER LETTERS (2016)
Targeting arachidonic acid pathway by natural products for cancer prevention and therapy
Nagendra Sastry Yarla et al.
SEMINARS IN CANCER BIOLOGY (2016)
Distinct effects of anti-inflammatory and anti-thrombotic drugs on cancer characteristics at diagnosis
Yudi Pawitan et al.
EUROPEAN JOURNAL OF CANCER (2015)
Inflammation and cancer: advances and new agents
Shanthini M. Crusz et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2015)
VWA domain of S5a restricts the ability to bind ubiquitin and Ubl to the 26S proteasome
Ravit Piterman et al.
MOLECULAR BIOLOGY OF THE CELL (2014)
Ubiquitination in disease pathogenesis and treatment
Doris Popovic et al.
NATURE MEDICINE (2014)
The degradation of p53 and its major E3 ligase Mdm2 is differentially dependent on the proteasomal ubiquitin receptor S5a
A. Sparks et al.
ONCOGENE (2014)
COX-2-derived endocannabinoid metabolites as novel inflammatory mediators
Mireille Alhouayek et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2014)
Ubiquitin receptors and protein quality control
Xuejun Wang et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2013)
Structure of Rpn10 and Its Interactions with Polyubiquitin Chains and the Proteasome Subunit Rpn12
Christiane Riedinger et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
The role of signaling pathways in the development and treatment of hepatocellular carcinoma
S. Whittaker et al.
ONCOGENE (2010)
Structure of the S5a:K48-Linked Diubiquitin Complex and Its Interactions with Rpn13
Naixia Zhang et al.
MOLECULAR CELL (2009)
Ubiquitin-binding domains - from structures to functions
Ivan Dikic et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2009)
Expression of cyclooxygenase-2 is regulated by glycogen synthase kinase-3β in gastric cancer cells
A Thiel et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
COX-2: A molecular target for colorectal cancer prevention
JR Brown et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Cyclooxygenase-2 and epidermal growth factor receptor: Pharmacologic targets for chemoprevention
AJ Dannenberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Signal transduction pathways regulating cyclooxygenase-2 expression: potential molecular targets for chemoprevention
KS Chun et al.
BIOCHEMICAL PHARMACOLOGY (2004)
Cyclooxygenase-2 (COX-2), aromatase and breast cancer: a possible role for COX-2 inhibitors in breast cancer chemoprevention
G Davies et al.
ANNALS OF ONCOLOGY (2002)